Quality of life may be affected more by disease parameters and response to therapy than by haemoglobin changes.

F. Wisløff, N. Gulbrandsen, M. Hjorth, S. Lenhoff, Peter Fayers

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Earlier studies showing a negative impact of anaemia on quality of life (QOL) lack adequate adjustment for confounding factors such as disease stage and tumour response. We examined the impact of haemoglobin concentration on QOL scores of 745 multiple myeloma patients followed from diagnosis, adjusting for objective disease parameters. Data from two Nordic studies with the EORTC QLQ-C30 questionnaire were analysed using linear regression analysis. Haemoglobin was independently related only to fatigue at baseline (P = 0.001) and at 12 months (P = 0.010). In multivariate analysis, extent of skeletal disease was at least as strong a predictor for fatigue at diagnosis as haemoglobin and was also related to other important QOL scores such as physical functioning, role functioning, global QOL and pain (P < 0.001). At 12 months' follow-up, response to therapy was related to physical functioning (P < 0.001) and pain (P = 0.001). In conclusion, haemoglobin and extent of skeletal disease were both predictors for fatigue in patients with newly diagnosed multiple myeloma, but extent Of skeletal disease was also associated with other important QOL scores. During follow-up, response to therapy emerged as an important predictor variable. When examining the effect of haemoglobin on QOL, it is essential to adjust for disease parameters and response to therapy in order not to overestimate the impact of haemoglobin on QOL. Our findings imply that uncontrolled studies on the effect of erythropoietin (EPO) in cancer patients may be making exaggerated claims for the effect of EPO on QOL.

Original languageEnglish
Pages (from-to)293-298
Number of pages6
JournalEuropean Journal of Haematology
Volume75
Issue number4
Early online date6 Sep 2005
DOIs
Publication statusPublished - Oct 2005

Keywords

  • quality of life
  • haemoglobin
  • myeloma
  • disease parameters
  • multiple regression
  • MULTIPLE-MYELOMA PATIENTS
  • PLACEBO-CONTROLLED TRIAL
  • EPOETIN-ALPHA
  • CANCER-PATIENTS
  • DOUBLE-BLIND
  • EUROPEAN-ORGANIZATION
  • CHEMOTHERAPY PATIENTS
  • MELPHALAN-PREDNISONE
  • COMMUNITY ONCOLOGY
  • MALIGNANCIES

Cite this

Quality of life may be affected more by disease parameters and response to therapy than by haemoglobin changes. / Wisløff, F.; Gulbrandsen, N.; Hjorth, M.; Lenhoff, S.; Fayers, Peter.

In: European Journal of Haematology, Vol. 75, No. 4, 10.2005, p. 293-298.

Research output: Contribution to journalArticle

@article{6a47acfd4e074e4c8d1ecd0c86f53ba3,
title = "Quality of life may be affected more by disease parameters and response to therapy than by haemoglobin changes.",
abstract = "Earlier studies showing a negative impact of anaemia on quality of life (QOL) lack adequate adjustment for confounding factors such as disease stage and tumour response. We examined the impact of haemoglobin concentration on QOL scores of 745 multiple myeloma patients followed from diagnosis, adjusting for objective disease parameters. Data from two Nordic studies with the EORTC QLQ-C30 questionnaire were analysed using linear regression analysis. Haemoglobin was independently related only to fatigue at baseline (P = 0.001) and at 12 months (P = 0.010). In multivariate analysis, extent of skeletal disease was at least as strong a predictor for fatigue at diagnosis as haemoglobin and was also related to other important QOL scores such as physical functioning, role functioning, global QOL and pain (P < 0.001). At 12 months' follow-up, response to therapy was related to physical functioning (P < 0.001) and pain (P = 0.001). In conclusion, haemoglobin and extent of skeletal disease were both predictors for fatigue in patients with newly diagnosed multiple myeloma, but extent Of skeletal disease was also associated with other important QOL scores. During follow-up, response to therapy emerged as an important predictor variable. When examining the effect of haemoglobin on QOL, it is essential to adjust for disease parameters and response to therapy in order not to overestimate the impact of haemoglobin on QOL. Our findings imply that uncontrolled studies on the effect of erythropoietin (EPO) in cancer patients may be making exaggerated claims for the effect of EPO on QOL.",
keywords = "quality of life, haemoglobin, myeloma, disease parameters, multiple regression, MULTIPLE-MYELOMA PATIENTS, PLACEBO-CONTROLLED TRIAL, EPOETIN-ALPHA, CANCER-PATIENTS, DOUBLE-BLIND, EUROPEAN-ORGANIZATION, CHEMOTHERAPY PATIENTS, MELPHALAN-PREDNISONE, COMMUNITY ONCOLOGY, MALIGNANCIES",
author = "F. Wisl{\o}ff and N. Gulbrandsen and M. Hjorth and S. Lenhoff and Peter Fayers",
note = "Acknowledgements F Wisloff designed the study and contributed to the statistical analysis. N Gulbrandsen designed the database and contributed to statistical analysis. M Hjorth and S Lenhoff helped design and maintain the database. P Fayers contributed to the statistical analysis. All investigators participated in the interpretation of the results and the preparation of the manuscript. There are no conflicts of interest. F Wisloff had access to all the data in the study and had final responsibility for the decision to submit for publication",
year = "2005",
month = "10",
doi = "10.1111/j.1600-0609.2005.00509.x",
language = "English",
volume = "75",
pages = "293--298",
journal = "European Journal of Haematology",
issn = "0902-4441",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Quality of life may be affected more by disease parameters and response to therapy than by haemoglobin changes.

AU - Wisløff, F.

AU - Gulbrandsen, N.

AU - Hjorth, M.

AU - Lenhoff, S.

AU - Fayers, Peter

N1 - Acknowledgements F Wisloff designed the study and contributed to the statistical analysis. N Gulbrandsen designed the database and contributed to statistical analysis. M Hjorth and S Lenhoff helped design and maintain the database. P Fayers contributed to the statistical analysis. All investigators participated in the interpretation of the results and the preparation of the manuscript. There are no conflicts of interest. F Wisloff had access to all the data in the study and had final responsibility for the decision to submit for publication

PY - 2005/10

Y1 - 2005/10

N2 - Earlier studies showing a negative impact of anaemia on quality of life (QOL) lack adequate adjustment for confounding factors such as disease stage and tumour response. We examined the impact of haemoglobin concentration on QOL scores of 745 multiple myeloma patients followed from diagnosis, adjusting for objective disease parameters. Data from two Nordic studies with the EORTC QLQ-C30 questionnaire were analysed using linear regression analysis. Haemoglobin was independently related only to fatigue at baseline (P = 0.001) and at 12 months (P = 0.010). In multivariate analysis, extent of skeletal disease was at least as strong a predictor for fatigue at diagnosis as haemoglobin and was also related to other important QOL scores such as physical functioning, role functioning, global QOL and pain (P < 0.001). At 12 months' follow-up, response to therapy was related to physical functioning (P < 0.001) and pain (P = 0.001). In conclusion, haemoglobin and extent of skeletal disease were both predictors for fatigue in patients with newly diagnosed multiple myeloma, but extent Of skeletal disease was also associated with other important QOL scores. During follow-up, response to therapy emerged as an important predictor variable. When examining the effect of haemoglobin on QOL, it is essential to adjust for disease parameters and response to therapy in order not to overestimate the impact of haemoglobin on QOL. Our findings imply that uncontrolled studies on the effect of erythropoietin (EPO) in cancer patients may be making exaggerated claims for the effect of EPO on QOL.

AB - Earlier studies showing a negative impact of anaemia on quality of life (QOL) lack adequate adjustment for confounding factors such as disease stage and tumour response. We examined the impact of haemoglobin concentration on QOL scores of 745 multiple myeloma patients followed from diagnosis, adjusting for objective disease parameters. Data from two Nordic studies with the EORTC QLQ-C30 questionnaire were analysed using linear regression analysis. Haemoglobin was independently related only to fatigue at baseline (P = 0.001) and at 12 months (P = 0.010). In multivariate analysis, extent of skeletal disease was at least as strong a predictor for fatigue at diagnosis as haemoglobin and was also related to other important QOL scores such as physical functioning, role functioning, global QOL and pain (P < 0.001). At 12 months' follow-up, response to therapy was related to physical functioning (P < 0.001) and pain (P = 0.001). In conclusion, haemoglobin and extent of skeletal disease were both predictors for fatigue in patients with newly diagnosed multiple myeloma, but extent Of skeletal disease was also associated with other important QOL scores. During follow-up, response to therapy emerged as an important predictor variable. When examining the effect of haemoglobin on QOL, it is essential to adjust for disease parameters and response to therapy in order not to overestimate the impact of haemoglobin on QOL. Our findings imply that uncontrolled studies on the effect of erythropoietin (EPO) in cancer patients may be making exaggerated claims for the effect of EPO on QOL.

KW - quality of life

KW - haemoglobin

KW - myeloma

KW - disease parameters

KW - multiple regression

KW - MULTIPLE-MYELOMA PATIENTS

KW - PLACEBO-CONTROLLED TRIAL

KW - EPOETIN-ALPHA

KW - CANCER-PATIENTS

KW - DOUBLE-BLIND

KW - EUROPEAN-ORGANIZATION

KW - CHEMOTHERAPY PATIENTS

KW - MELPHALAN-PREDNISONE

KW - COMMUNITY ONCOLOGY

KW - MALIGNANCIES

U2 - 10.1111/j.1600-0609.2005.00509.x

DO - 10.1111/j.1600-0609.2005.00509.x

M3 - Article

VL - 75

SP - 293

EP - 298

JO - European Journal of Haematology

JF - European Journal of Haematology

SN - 0902-4441

IS - 4

ER -